Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients

Fig. 2

CD133 expression was decreased using the lentiviral vector pLKO/shCD133, and the CD133 antibody (orb18124, Biorbyt) was used to validate CD133 protein expression level and location in liver cancer cells. a CD133 expression was depleted upon transfection of HepG2 and PLC-5 cells with pLKO/shCD133. The CD133 protein expression levels were evaluated using western blotting. β-actin was used as a loading control. b CD133 antibody (orb18124, Biorbyt) was used to probe CD133 location in PLC-5 cells with pLKO and pLKO/shCD133 at 4 °C overnight, which was followed by binding the antibody with Alexa Flour 488 goat anti-Rabbit to produce green fluorescence, which was observed with a Leica DM2500 upright fluorescence microscope. The nuclei were stained with 4′,6′-diamidino-2-phenylindole (DAPI)

Back to article page